Glenn Begley was stymied. At the drug giant Amgen, where Begley was vice-president and global head of hematology and oncology research, he was struggling to repeat an animal study of tumor growth by a respected oncologist, published in Cancer Cell. One figure stood out as particularly impressive. But it was proving stubbornly resistant to replication. In March of 2011, Begley saw a chance to play detective. At the annual meeting of the American Association for Cancer Research in Orlando, he and a colleague invited the paper's senior author out to breakfast. Across his orange juice and oatmeal, Begley floated the question: Why couldn't his group get the same finding as the oncologist?
展开▼